ID: ALA5194451

Max Phase: Preclinical

Molecular Formula: C25H26FN7O2

Molecular Weight: 475.53

Representations

Canonical SMILES:  CCN1CCN(C(=O)c2ccc(Nc3ncc(F)c(-c4ccc5c(c4)CCNC5=O)n3)nc2)CC1

Standard InChI:  InChI=1S/C25H26FN7O2/c1-2-32-9-11-33(12-10-32)24(35)18-4-6-21(28-14-18)30-25-29-15-20(26)22(31-25)17-3-5-19-16(13-17)7-8-27-23(19)34/h3-6,13-15H,2,7-12H2,1H3,(H,27,34)(H,28,29,30,31)

Standard InChI Key:  PZNJKWXGJKXLOU-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 475.53

Molecular Weight (Monoisotopic): 475.2132

AlogP: 2.48

#Rotatable Bonds: 5

Polar Surface Area: 103.35

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.62

CX Basic pKa: 7.04

CX LogP: 2.34

CX LogD: 2.18

Aromatic Rings: 3

Heavy Atoms: 35

QED Weighted: 0.58

Np Likeness Score: -1.28

References

1. Chen W, Ji M, Cheng H, Zheng M, Xia F, Min W, Yang H, Wang X, Wang L, Cao L, Yuan K, Yang P..  (2022)  Discovery, Optimization, and Evaluation of Selective CDK4/6 Inhibitors for the Treatment of Breast Cancer.,  65  (22.0): [PMID:36350721] [10.1021/acs.jmedchem.2c00947]

Source

Source(1):

• Scientific Literature